DISCOVER OUR NEWS
TheraPPI Bioscience announces an exclusive license agreement with PULSALYS to develop novel drugs in oncology and rare diseases
PULSALYS and TheraPPI Bioscience SAS enter into an exclusive and global license agreement to develop drugs targeting a novel Ras-MAPK pathway protein interaction